July 14, 2017 09:32 AM EDT
Financing

Akcea IPO stum­bles and falls well be­low the range, but still rais­es $175M

John Carroll

Editor & Founder

In­vestors weren’t will­ing to pay what Akcea Ther­a­peu­tics $AK­CA want­ed for their IPO shares, but by adding to the load of stock on of­fer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

An­oth­er round of con­sol­i­da­tion is com­ing, FDA com­mis­sion­er tells staff

Bris­tol My­ers gets a key strate­gist with 'Team Shib­s'; Idor­sia to change CEOs af­ter it 'hit a re­set but­ton'

Rein Ther­a­peu­tics study on clin­i­cal hold; Beam up­dates sick­le cell ther­a­py da­ta

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

As­traZeneca inks AI drug R&D deal with Chi­nese phar­ma for $110M up­front 

sponsored

McKesson leads the charge in rev­o­lu­tion­iz­ing pre­ci­sion on­col­o­gy in com­mu­ni­ty prac­tices

A service from the Financial Times